Standard Chem & Pharm Co., Ltd. Stock Symbol : 1720

2026 Investor Conference 03/12/2026

==> picture [508 x 268] intentionally omitted <==

==> picture [320 x 85] intentionally omitted <==

免責聲明 Safe Harbor Notice

==> picture [98 x 91] intentionally omitted <==

本次簡報與討論包含特定預測性的說明，而其內容有關於營運結果、財務狀況，以及對未來事件的預期。因為此等前瞻性說明是有關於未來事件，而且取決於未來發生時的環境因素，所以必然含有風險與不確定性。

本公司將不負擔公開更新或修改這些預測性的說明之義務，無論是出現新資訊、未來發生任何事件，或其他情況。實際結果可能與此等預測性說明推測的內容有重大差異。

In these presentations and discussions, there are certain forward looking statements regarding the results of operation, financial condition and current expectation about future events. As forward-looking statements relate to events and depend on circumstances in the future, they involve risk and uncertainty. We do not undertake any obligation to publicly revise or update any forward looking statements for availability of new information, future events or otherwise. Real result probably differ substantially from those expected in these forward-looking statements.

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

1
----- End of picture text -----

==> picture [98 x 91] intentionally omitted <==

Agenda

⚫ Introduction of Standard Group

⚫ 2025 Operating Results

⚫ Future Operation Strategy

⚫ Environmental, Social, and Governance(ESG)

==> picture [98 x 91] intentionally omitted <==

Agenda

⚫ Introduction of Standard Group

⚫ 2025 Operating Results

⚫ Future Operation Strategy ⚫ Environmental, Social, and Governance(ESG)

SCP and Related / Affiliated Com anies p

==> picture [730 x 426] intentionally omitted <==

----- Start of picture text -----

Upstream Manufacture Channels
Syn-Tech (1982; 2005
SCP(1967;
Taiwan Biosim(2017)
Over-The-Counter OTC)
Western 1995 listed stock)
medicine
Your Chance
Syngen(1999; 2016 OTC) Souriree(1997)
(Invested in 2013;
2024.03 OTC)
Syngen(1999)
Healthcare Multipower
nutrition (Invested in 2012)
Sun-you(1994)
Medical- Syngen (1999)
devices
Ho Yao Biopharm (2021)
Obtained CRO certification In October 2023
----- End of picture text -----

==> picture [100 x 13] intentionally omitted <==

----- Start of picture text -----

© 2026 SCP, Ltd
----- End of picture text -----

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 69] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

4
----- End of picture text -----

International Accreditation

==> picture [104 x 46] intentionally omitted <==

----- Start of picture text -----

2000
----- End of picture text -----

==> picture [104 x 46] intentionally omitted <==

----- Start of picture text -----

2009
----- End of picture text -----

==> picture [104 x 46] intentionally omitted <==

----- Start of picture text -----

2017
----- End of picture text -----

==> picture [104 x 47] intentionally omitted <==

----- Start of picture text -----

2025
----- End of picture text -----

==> picture [47 x 50] intentionally omitted <==

==> picture [32 x 42] intentionally omitted <==

. The first pharmaceutical company in Taiwan to receive ISO 9001 certification in 1998

==> picture [56 x 35] intentionally omitted <==

==> picture [51 x 28] intentionally omitted <==

The first TW company to pass US FDA inspection in 2000

Subsequent US FDA GMP inspections : no 483 Last Inspection : 2022/10/31

==> picture [31 x 42] intentionally omitted <==

Passed JP PMDA GMP inspection in 2018(Follow-up inspection passed in May 2025)

SCP received JP PMDA’s “Certificate of Foreign Drug Manufacturer” in 2008

==> picture [56 x 34] intentionally omitted <==

==> picture [64 x 41] intentionally omitted <==

2009

==> picture [54 x 37] intentionally omitted <==

SCP’s API plant passed AU TGA inspection

==> picture [50 x 39] intentionally omitted <==

==> picture [54 x 40] intentionally omitted <==

2010 SCP passed TW PIC/S GMP inspection 2012 SCP is certified GDP by the T-FDA

==> picture [54 x 38] intentionally omitted <==

==> picture [80 x 33] intentionally omitted <==

2012 SCP passed K-FDA inspection

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 69] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

5
----- End of picture text -----

==> picture [98 x 91] intentionally omitted <==

Agenda

⚫ Introduction of Standard Group

⚫ 2025 Operating Results

⚫ Future Operation Strategy ⚫ Environmental, Social, and Governance(ESG)

Consolidated Income Statement

Items	2025	2024	Diff.	Annual changes (%)
(Unless otherwise specified, expressed in thousands of New Taiwan Dollars)
Operating revenue	7,023,025	6,789,223	233,802	3.4%
Gross profit	2,908,809	2,988,691	(79,882)	(2.7%)
Gross profit margin	41.42%	44.02%		(2.6%)
Operating expenses	1,546,017	1,592,375	(46,358)	(2.9%)
Operating profit	1,362,792	1,396,316	(33,524)	(2.4%)
Non-operating income and expenses	151,084	231,043	(79,959)	(34.6%)
Profit before income tax	1,513,876	1,627,359	(113,483)	(7.0%)
Profit for the year	1,255,529	1,294,310	(38,781)	(3.0%)
Profit attributable to Shareholders of the parent	927,659	880,501	47,158	5.4%
EPS(NTD)	5.19	4.93	0.26	5.4%
2026 SCP, Ltd

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q 7

Comparison of Quarterly Revenue of Past 5 Years (Consolidated)

	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 2,000,000 Q1 Q2 Q3 Q4 2021 2022 2023 2024 2025 *Expressed in thousands of NTD* 21 21 22 24 25 23 21 22 24 25 23 21 22 24 25 23 21 22 24 23 25	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 2,000,000 Q1 Q2 Q3 Q4 2021 2022 2023 2024 2025 *Expressed in thousands of NTD* 21 21 22 24 25 23 21 22 24 25 23 21 22 24 25 23 21 22 24 23 25	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 2,000,000 Q1 Q2 Q3 Q4 2021 2022 2023 2024 2025 *Expressed in thousands of NTD* 21 21 22 24 25 23 21 22 24 25 23 21 22 24 25 23 21 22 24 23 25	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 2,000,000 Q1 Q2 Q3 Q4 2021 2022 2023 2024 2025 *Expressed in thousands of NTD* 21 21 22 24 25 23 21 22 24 25 23 21 22 24 25 23 21 22 24 23 25	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 2,000,000 Q1 Q2 Q3 Q4 2021 2022 2023 2024 2025 *Expressed in thousands of NTD* 21 21 22 24 25 23 21 22 24 25 23 21 22 24 25 23 21 22 24 23 25	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 2,000,000 Q1 Q2 Q3 Q4 2021 2022 2023 2024 2025 *Expressed in thousands of NTD* 21 21 22 24 25 23 21 22 24 25 23 21 22 24 25 23 21 22 24 23 25
	Q1	Q2	Q3	Q4	Total	Growth(%)
2021	1,101,113	1,149,060	1,120,840	1,233,069	4,604,082	+6.9%
2022	1,237,170	1,481,061	1,549,872	1,583,265	5,851,368	+27.1%
2023	1,493,025	1,509,004	1,645,531	1,592,208	6,239,768	+6.6%
2024	1,613,535	1,760,104	1,742,442	1,673,142	6,789,223	+8.8%
2025	1,640,034	1,827,915	1,769,689	1,785,387	7,023,025	+3.4%

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Consolidated Balance Sheet

Items	2025	2025	2024	2024	Diff.	Annual changes(%)
*(Expressed in thousands of NTD)*	Amount	%	Amount	%
Cash and cash equivalents	1,833,746	15.5%	1,520,128	13.6%	313,618	20.6%
Accounts receivable	1,370,646	11.6%	1,339,410	12.0%	31,236	2.3%
Inventories	1,569,221	13.3%	1,720,381	15.4%	(151,160)	(8.8%)
Investments	1,769,848	15.0%	1,499,821	13.4%	270,027	18.0%
Property,plant and equipment	4,225,363	35.8%	4,128,811	36.9%	96,552	2.3%
Others	1,027,079	8.7%	966,994	8.7%	60,085	6.2%
Total Assets	11,795,903	100.0%	11,175,545	100.0%	620,358	5.6%
Current Liabilities	2,156,966	18.3%	1,660,932	14.9%	496,034	29.9%
Non-current Liabilities	352,128	3.0%	538,545	4.8%	(186,417)	(34.6%)
Total liabilities	2,509,094	21.3%	2,199,477	19.7%	309,617	14.1%
Total shareholder’s equity	9,286,809	78.7%	8,976,068	80.3%	310,741	3.5%
2026 SCP, Ltd Debt Ratio(Liabilities/Assets) 21.3% 19.7%

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q 9

Consolidated Cash Flows

Consolidated Cash Flows
Items	2025	2024	Q 10
*(Expressed in thousands of NTD)*
Cash at beginning of year	1,520,128	2,036,743
Cash flows from operating activities	1,766,827	1,694,941
Investment	(542,247)	(192,351)
Acquisition of property, plant and equipment	(492,866)	(596,477)
Cash dividends	(500,349)	(482,479)
Short & long-term borrowings	390,973	(749,027)
Others	(308,720)	(191,222)
Cash at end of year	1,833,746	1,520,128

2026 SCP, Ltd Free cash flow (Cash flows from operating activities-Acquisition of property, plant and equipment) 1,273,961 1,098,464

==> picture [919 x 512] intentionally omitted <==

----- Start of picture text -----

1720 SCP net rofit after tax and EPS in 2025
p
NTD Thousand NTD
1,000,000 6.00
5.19
900,000 4.93
4.56 4.67 5.00
800,000
3.95
700,000
4.00
600,000
2.93
500,000 3.00
400,000 2.09 1.95 1.90 2.03 2.09 2.11 2.70 2.80
2.50
2.00
1.61 1.73 2.00
300,000 1.47 2.50
1.80
1.60 1.50
200,000 1.50 1.50
1.50 1.00
1.20 2.50
Q
100,000
1.00 1.00
1.00
0 0.00
11
© 2026 SCP, Ltd
----- End of picture text -----

1777 SYN-TECH’s net rofit after tax and EPS in 2025 p

NTD Thousand

NTD

==> picture [784 x 407] intentionally omitted <==

----- Start of picture text -----

8.82
400,000 9.00
8.00
350,000
6.62
7.00
300,000 6.21 5.87
6.00
5.20 5.27 5.31
250,000 4.93 5.12
5.63
5.00
5.03
200,000
4.00
3.10
150,000
1.99
3.00
2.19 4.00 5.3
1.89
100,000 3.30 4.0
2.00
3.50 3.50
3.00
1.30 3.50 1.75
50,000 2.00 3.00 3.50 1.93 1.00
1.00 0.50
0 0.00
© 2026 SCP, Ltd
----- End of picture text -----

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

8279 Syngen’s net profit after tax and EPS in 2025

NTD Thousand

==> picture [789 x 393] intentionally omitted <==

----- Start of picture text -----

NTD Thousand NTD
400,000 14.00
11.85
350,000
12.00
10.14 10.02
300,000
10.00
8.77 8.86
250,000 7.86 7.95
8.00
6.43
200,000
5.8
6.00
4.69
150,000
3.76
4.00
100,000
3.50
2.04 4.00
5.00 5.00 5.00 5.00
2.00
50,000
1.00 1.00 2.50
3.00
0.50
0.00 1.00
0 0.00
----- End of picture text -----

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 69] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [98 x 91] intentionally omitted <==

Agenda

⚫ Introduction of Standard Group

⚫ 2025 Operating Results

⚫ Future Operation Strategy

⚫ Environmental, Social, and Governance(ESG)

Future Milestone

==> picture [794 x 100] intentionally omitted <==

==> picture [130 x 166] intentionally omitted <==

From Taiwan to International From Generics to Better than Generics (BTG)

==> picture [300 x 77] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 69] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

Revenue Growth Strate - Taiwan gy

==> picture [144 x 206] intentionally omitted <==

Company EPS 2025 SCP (1720) 5.19 Syn-Tech (1777) 5.87 Syngen (8279) 10.02

⚫ Focusing on four key business areas with excellent operational capabilities and a strong management team.

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

➢ Western medicine formulations, APIs, health supplements, and retail chain channels.

==> picture [98 x 91] intentionally omitted <==

Si nificant Business Activities in Recent Years g

Taiwan China Japan • • • 6 Products Expected to Launch Cumulative In-House Marketing Authorizations: 3 cases 2 cases (bronchiolitis and in 2026 First-to-Market OAB Product: (Erectile dysfunction, diabetes,and ALS) 1 products • • Accumulated technology CNS: 2 products 2 cases transfer licenses: 3 cases Diabetes drug: 1 Product • • Consistency Evaluation(GQCE) Gastrointestinal: 1 Product 4 cases 1 cases. reviews in progress: Expectorant: 1 Product • • : 3 cases. In Development

==> picture [31 x 27] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

Continues to be sold: 2 cases (bronchiolitis and oral anti-inflammatory and pain relief medications.)

==> picture [64 x 63] intentionally omitted <==

Contracts in progress: 2 cases

==> picture [64 x 63] intentionally omitted <==

In Development: 4 cases
CDMO Under Discussion 1 cases
• New in-licensed drug: Q
1 cases (Gout) 17
2026 Global Marketing Team: Taiwan team: 180 members
Vietnam team: 25members Philippines team: 19 members

==> picture [37 x 37] intentionally omitted <==

International Market Expansion and Collaboration Model

International Market Expansion

Primary sales markets: Southeast Asian countries, South Korea, Japan, and China.
Actively expanding into Europe, the U.S., and Canada.

Licensing Collaboration

Adopting a diversified collaboration approach by licensing registered products to local partners for sales.
Seeking original brand agency rights to enhance competitiveness in the Taiwan market.

CDMO / CMO

In recent years, collaboration with major Japanese pharmaceutical companies on CDMO projects has laid a solid foundation for SCP presence in the Japanese market.

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

Actively pursuing additional CDMO / CMO partnerships to continuously drive revenue growth.

China’s Generic Pharmaceutical Market –

==> picture [98 x 91] intentionally omitted <==

Transformation Toward Higher Quality and Differentiation

Market Overview

Policy Direction: High-Quality Development

Operational Challenges: Policy and Pricing Pressure
NMPA emphasizes quality and efficiency in generic drug consistency evaluation
Ongoing expansion of centralized procurement intensifies price competition
• Regulatory review and technical requirements becoming more stringent
Strengthened quality supervision for products selected under centralized procurement
Market Orientation: Encouraging Differentiated Products
Increasing project risks and uncertainties
Industry Transformation: Rapid Growth of Innovative Drugs
Four batches of recommended generic drug lists have been released
Focus on products with expiring patents and insufficient supply
Parallel development of innovative R&D and overseas licensing

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

Market shifting from price competition to value competition

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

19
----- End of picture text -----

China’s Generic Pharmaceutical Market – O ortunities for SCP pp

==> picture [98 x 91] intentionally omitted <==

Strategic Response and Growth Drivers

Focus on high-quality and high-barrier products to avoid low-price competition.

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Strengthen API strategic alliances to enhance supply stability and cost advantages.
Establish a differentiated positioning of “Manufactured in Taiwan, Imported into China.”

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 69] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

U.S. Generic Pharmaceutical Market

Market Overview

Project Economics Challenges

Rising Drug Pricing Policy and Market Pressure

Accelerating price erosion shortens the investment payback periodProduct selection and differentiation capabilities have become critical success factors.
Drug pricing continues to receive significant political and policy attention. Following the implementation of the Inflation Reduction Act (IRA), market expectations for pricing have become more conservative.
Intensifying Market Competition

Increasingly Stringent Regulatory and Quality Requirements

The FDA has raised expectations for data integrity and regulatory compliancePostlaunch supply reliability and quality track record have become key partnership thresholds.
Fierce competition among first generics, with faster price erosion after product launch.The number of market entrants and timing of entry are key factors determining project economics.

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

21
----- End of picture text -----

U.S. Generic Pharmaceutical Market – O ortunities for SCP pp

Strategic Initiatives

Leverage patent challenges and proprietary patent portfolio to establish dual market entry barriers and strengthen market exclusivity.
Adopt a multi-regional partnering strategy to diversify market and pricing risks and extend the investment payback period.
Form strategic alliances with API manufacturers to enhance cost competitiveness and supply stability.

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 69] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

Japan’s Generic Pharmaceutical Market – AG and Bio-AG Pricin Polic Ad ustments g y j Generic Pharmaceutical Reform: AG and Bio-AG Pricing Policy Adjustments

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

Current System: Priced in line with generic drug pricing rules

AG products have the same ingredients, API, excipients, and manufacturing process as the originator drugs and currently hold a dominant market share.
Current pricing: AG at 50% of the originator drug price; Bio-AG at 70%.
After Reform: Same pricing as originator drugs
Market reshuffling expected: As the pricing advantage of AG products diminishes, generic manufacturers with strong in-house R&D capabilities or superior cost control may regain market share.

==> picture [64 x 63] intentionally omitted <==

Japan’s Generic Pharmaceutical Market – O ortunities for SCP pp

Market Positioning and Differentiation Strategy

1. Establish deep collaborations and strategic alliances with API manufacturers to ensure stable supply and effective cost control.

2. Focus on high-margin generic drugs by avoiding originator patents and filing applications at the earliest opportunity, while pursuing formulation differentiation to meet the needs of an aging market.

“ Centering on technology and R&D, the Company focuses on differentiated generic drugs and strengthens cost and supply chain competitiveness through strategic alliances with API manufacturers.By partnering with CDMO collaborators, it aims to expand production capacity and broaden its presence in the Japanese market.”

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

24
----- End of picture text -----

Revenue Growth Strate - China gy

==> picture [80 x 81] intentionally omitted <==

Strategy

==> picture [77 x 61] intentionally omitted <==

Achievements in getting licenses

Own brand and tech transfer simultaneously
3 cases for tech transfer
- 3 case for import license
CDMO
Expand the number of collaborative projects and pharmaceutical companies

NMPA Consistency Evaluation

 1 cases submitted for evaluation

Medium-term targets

Self-developed products submission
Tech transfer profit sharing revenue

Project initiation/Research in progress

Cooperation

Tech-transfer
3 cases in progress
Joint ownership of License
Cooperative production and marketing
Profit-sharing Partnerships

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 69] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

Revenue Growth Strate - Ja an gy p

==> picture [80 x 71] intentionally omitted <==

==> picture [76 x 72] intentionally omitted <==

Strategy

Collaboration Model

Distribution of Originator Innovative Drugs.
CDMO / CMO
Collaboration with Japanese Pharmaceutical Companies in Other Markets.
Japan marketing partner
Strategic Alliances / Vertical Integration with API Manufacturers

==> picture [78 x 74] intentionally omitted <==

----- Start of picture text -----

•
----- End of picture text -----

Current State

On Going

2 items continue sales
CDMO/CMO
2 under PMDA review
Common items for China/ Southeast Asia/ Japan are under discussion
4 products currently under development
Actively pursuing CMO partnerships and innovative drug licensing

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

26
----- End of picture text -----

Revenue Growth Strate - U.S. gy

==> picture [80 x 71] intentionally omitted <==

==> picture [76 x 72] intentionally omitted <==

Strategy

Collaboration Model

Distribution of Originator Innovative Drugs.
CDMO: Partner holds the license
Strategic Alliances with API

and manages commercialization

Vertical Integration with Syn-Tech and API Operations
CMO

==> picture [78 x 74] intentionally omitted <==

----- Start of picture text -----

•
----- End of picture text -----

Current State

On Going

2 items continue sales
(Lipid-Lowering Therapy, ALS)
CDMO/CMO
2 Products in Development; Actively Seeking Partners
Actively pursuing innovative drug distribution opportunities

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 69] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

27
----- End of picture text -----

==> picture [938 x 539] intentionally omitted <==

----- Start of picture text -----

Strate ies for Addressin Globalization Challen es
g g g
Agency for
Strategic Alliance Self-Challenge First-to-File
Branded Drugs
Strengthen Supply Complex / Patent- Gaining the Early Fulfilling Market
Stability and Cost Challenged Market Entry Needs for
Advantage Generics Advantage Pharmaceuticals
Q
28
© 2026 SCP, Ltd
----- End of picture text -----

==> picture [98 x 91] intentionally omitted <==

Agenda

⚫ Introduction of Standard Group ⚫ 2025 Operating Results

⚫ Future Operation Strategy

⚫ Environmental, Social, and Governance(ESG)

==> picture [98 x 91] intentionally omitted <==

Net Zero Emissions and Sustainable Develo ment p

Energy Management

Waste Management

==> picture [64 x 64] intentionally omitted <==

• Engaged qualified waste disposal and recycling companies for waste removal and resource recovery. • A waste disposal plan is submitted in accordance with regulations and implemented upon official approval.Only legally registered waste transporters and treatment facilities with Class A certification are selected for handling and processing.

Replacement of 180 T5 fluorescent grid ceiling lights with LED panel lights.
Upgrade of 25HP fixed-speed air compressor to 30HP variablespeed air compressor at the Liquid High Plant.

==> picture [64 x 63] intentionally omitted <==

By implementing regular maintenance, conducting wastewater quality testing, improving system parameters, and optimizing water production conditions, we effectively reduce carbon emissions, enhance cost efficiency, and conserve energy.

==> picture [64 x 63] intentionally omitted <==

Water Resource Management

Optimize production processes and product design to reduce water usage and enhance production efficiency.
Give priority to the use of water-saving equipment to reduce water loss.
Treated wastewater from the wastewater treatment plant Q
was supplied to the Environmental Protection Bureau for street cleaning, providing 304 tons of water in 2025.
Ensure regular maintenance and inspection of pipelines to minimize water leakage and wastage.
Periodically disclose the company's water consumption to raise employee awareness on the importance of conserving water resources.

==> picture [389 x 60] intentionally omitted <==

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

30
----- End of picture text -----

Awarded the Taiwan BIO Awards – Outstandin Com an of the Year g p y

Awarded the Gold Award 3 times (2014, 2021, and 2025)

==> picture [324 x 216] intentionally omitted <==

==> picture [255 x 245] intentionally omitted <==

==> picture [257 x 146] intentionally omitted <==

==> picture [217 x 308] intentionally omitted <==

==> picture [219 x 84] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 73] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

Recognized as an Outstanding Enterprise for Green Procurement

Invited to the Tainan City Environmental Protection Excellence Awards Ceremony (Dec. 18, 2025) and honored as the 2024 Outstanding Green Procurement Enterprise of Tainan City.

==> picture [98 x 91] intentionally omitted <==

==> picture [18 x 16] intentionally omitted <==

==> picture [220 x 331] intentionally omitted <==

Protectin the Ocean : Beach Cleanu Activit g p y

⚫ For two consecutive years, employees have voluntarily initiated beach cleanup activities, with a total of 108 participants. A cumulative 1,092 meters of shoreline were cleaned, and 126 kilograms of trash were removed.

==> picture [261 x 156] intentionally omitted <==

==> picture [489 x 322] intentionally omitted <==

==> picture [260 x 176] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 73] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

Social Care and En a ement - Fan Dao Nan Foundation g g

Introduction to the foundation

==> picture [184 x 136] intentionally omitted <==

Established in 1987
Endowment Fund: NT$202.26 Million
Annual Budget: NT$14 Million

==> picture [184 x 135] intentionally omitted <==

Principal Activities

Cultural and educational development activities
Public education affairs
Children’s education and happiness
Scholarships and Talent Cultivation

==> picture [186 x 136] intentionally omitted <==

Rewards and Honors Received

2011: Special Recognition Award – Ministry of Education
2012: Tainan City Govt. Grant for Scholarship Program
2013: National Special Selection Award for

After-School Program – Dept. of Education

2022: Group Award on Social Education Contribution by Ministry Of Education

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

34
----- End of picture text -----

	Social Care and Community Engagement	Social Care and Community Engagement	Social Care and Community Engagement	Social Care and Community Engagement	–
	2025 Social Welfare Contributions: NT$13.91 million

	Scholarships		Hope After-school Class		Sunflower Wednesdays
	• High school :
	8 schools, totaled 144 students • Middle school :	•	Weekday afternoons	•	Every Wednesday afternoons
	59 schools, totaled 785 students	•	21 schools, 1,018 students	•	8 Schools, 410 students
	• Elementary school :
	233 schools, totaled 2,629 students
	NTD 7.72 million		NTD 1.19 million		NTD 0.40 million
	Other Sponsorships		Meal-Assistance		Charity
	• Sponsor 17 public welfare
	organizations.	•	Provided 6,630 meals	•	SCP Children’s Drawing
	(Chi Po-lin Foundation、Tainan City Social Affairs Bureau – Child and Youth Savings			•	Competition NTD 0.54 million SCP National Table Tennis	Q
	Account Program, Donations for Typhoon Danas Relief – Xinying District Office, Yijhu Township Office, and others)				Competition NTD 2.11 million (Estimated Expenses)
©	NTD 1.31 million 2026 SCP, Ltd		NTD 0.64 million		NTD 2.65 million	35

==> picture [930 x 540] intentionally omitted <==

----- Start of picture text -----

Social Care and Engagement -
The 40th SCP Children's Drawin Com etition
g p
⚫ Held on September 27, 2025, at Wanpi World Safari Zoo, with 530 participating
students and 576 accompanying teachers and parents, totaling 1,106 people.
Q
Kindergarten Category - Lower Grade Category - Middle Grade Category - Upper Grade Category -
Gold Award Gold Award Gold Award Gold Award
36
© 2026 SCP, Ltd
----- End of picture text -----

Social Care and Engagement - The 40th SCP National Table Tennis Com etition p

==> picture [346 x 218] intentionally omitted <==

==> picture [352 x 221] intentionally omitted <==

==> picture [292 x 214] intentionally omitted <==

A total of 293 teams and 2,177 participants competed in the event held for three consecutive days starting December 5, 2025, at the Tainan Municipal Xinying Stadium.

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

Social Care and Engagement - Senior Gym - Dotcom S orts & Health Center p

==> picture [461 x 247] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [156 x 207] intentionally omitted <==

Year 2025

⚫ Total usage reached 170,226 visits.
⚫ Held 42 “Healthy and Active Living” seminars (Including 28 physical fitness classes and 14 health seminars), providing nutritional care education, strength training, and fitness programs for the elderlyAwarded the Sustainable Operations.

Q

⚫ Awarded the 2024 Tainan City Public Health Bureau Silver Club Program – Sustainable Management Award.

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

38
----- End of picture text -----

Social Care and Engagement - Annual Blood Donation Drive with Grou Em lo ees p p y

==> picture [98 x 91] intentionally omitted <==

⚫ 196,000 cc of Blood Donated Over the Past Three Years

==> picture [634 x 343] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

39
----- End of picture text -----

==> picture [98 x 91] intentionally omitted <==

Q & A

==> picture [64 x 65] intentionally omitted <==

AI assistant

S.C.P.C — Annual Report 2025

51900_rns_2026-03-11_085ac9bb-db58-4de6-8885-38bbbff45175.pdf

免責聲明 Safe Harbor Notice

Agenda

Agenda

SCP and Related / Affiliated Com anies p

International Accreditation

Agenda

Consolidated Income Statement

Comparison of Quarterly Revenue of Past 5 Years (Consolidated)

Consolidated Balance Sheet

Consolidated Cash Flows

1777 SYN-TECH’s net rofit after tax and EPS in 2025 p

NTD Thousand

8279 Syngen’s net profit after tax and EPS in 2025

NTD Thousand

Agenda

Future Milestone

From Taiwan to International From Generics to Better than Generics (BTG)

Revenue Growth Strate - Taiwan gy

Si nificant Business Activities in Recent Years g

International Market Expansion and Collaboration Model

International Market Expansion

Licensing Collaboration

CDMO / CMO

Q

China’s Generic Pharmaceutical Market –

Transformation Toward Higher Quality and Differentiation

Market Overview

Policy Direction: High-Quality Development

Q

China’s Generic Pharmaceutical Market – O ortunities for SCP pp

Strategic Response and Growth Drivers

U.S. Generic Pharmaceutical Market

Market Overview

Rising Drug Pricing Policy and Market Pressure

U.S. Generic Pharmaceutical Market – O ortunities for SCP pp

Strategic Initiatives

Japan’s Generic Pharmaceutical Market – AG and Bio-AG Pricin Polic Ad ustments g y j Generic Pharmaceutical Reform: AG and Bio-AG Pricing Policy Adjustments

Current System: Priced in line with generic drug pricing rules

Japan’s Generic Pharmaceutical Market – O ortunities for SCP pp

Market Positioning and Differentiation Strategy

Revenue Growth Strate - China gy

Strategy

Achievements in getting licenses

NMPA Consistency Evaluation

Medium-term targets

Cooperation

Revenue Growth Strate - Ja an gy p

Strategy

Collaboration Model

Current State

On Going

Q

Revenue Growth Strate - U.S. gy

Strategy

Collaboration Model

Current State

Agenda

Net Zero Emissions and Sustainable Develo ment p

Energy Management

Waste Management

Water Resource Management

Awarded the Taiwan BIO Awards – Outstandin Com an of the Year g p y

Recognized as an Outstanding Enterprise for Green Procurement

Protectin the Ocean : Beach Cleanu Activit g p y

Social Care and En a ement - Fan Dao Nan Foundation g g

Introduction to the foundation

Principal Activities

Rewards and Honors Received

Q

Social Care and Engagement - The 40th SCP National Table Tennis Com etition p

Social Care and Engagement - Senior Gym - Dotcom S orts & Health Center p

Q

Social Care and Engagement - Annual Blood Donation Drive with Grou Em lo ees p p y

Q & A

More from S.C.P.C

S.C.P.C Annual Report 2025